NCT06828172

Brief Summary

INTRODUCTION: Exercise with an arm ergometer (EB) overcomes the main barrier to physical exercise in patients with Peripheral Artery Disease (PAD), leg pain during walking. Due to its aerobic nature, this type of exercise can cause systemic changes in the regulatory mechanisms of vasodilation. In other words, it provides vascular benefits in the most affected arterial beds in the PAD population. OBJECTIVE: To analyze local and systemic vascular responses, as well as cell signaling pathways after an EB exercise session in patients with PAD and their peers without PAD. METHODS: 24 patients with PAD and 24 individuals without PAD will be recruited, matched by sex and age. Participants will undergo two experimental sessions in approved order (EB and control). The EB session will consist of 15 cycles of 2 min of exercise with an intensity equivalent to 13-15 on the Borg scale of perceived exertion. Before and after the experimental sessions, the vascular function of the brachial and femoral arteries, blood indicators of vasodilation and calf muscle oxygenation will be evaluated. To analyze the acute effect between groups on cardiovascular parameters, a three-way analysis of variance will be performed, taking as factors disease (presence vs. absence), session (EB vs. Control) and time (pre vs. post). In all analyses, when a significant effect is selected, the Bonferroni or Newman-Keuls post-hoc test will be used. For all analyses, a value of P\<0.05 will be considered significant.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
14mo left

Started Mar 2025

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress50%
Mar 2025Jul 2027

First Submitted

Initial submission to the registry

February 10, 2025

Completed
4 days until next milestone

First Posted

Study publicly available on registry

February 14, 2025

Completed
1 month until next milestone

Study Start

First participant enrolled

March 24, 2025

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 15, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 15, 2027

Last Updated

April 13, 2026

Status Verified

April 1, 2026

Enrollment Period

2.3 years

First QC Date

February 10, 2025

Last Update Submit

April 7, 2026

Conditions

Keywords

Intermittent claudicationExerciseVascular function

Outcome Measures

Primary Outcomes (1)

  • Calf Muscle Oxygen Saturation (%)

    The parameters of calf muscle oxygenation will be collected using the non-invasive Near-Infrared Spectroscopy (NIRS) technique, with an NIRS spectrometer and a dedicated laptop computer. The NIRS sensor will be placed on the calf region, on the leg with the lower ankle brachial index, at the level of the largest calf circumference. The equipment will be programmed for continuous recording throughout the experimental session, covering the pre-exercise, during exercise with arm ergometer, and post-exercise periods.

    Just before, during 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 minutes of exercise, and after 10 minutes of exercise.

Secondary Outcomes (5)

  • Change from baseline in vascular function post-exercise in the brachial and femoral arteries (%).

    Before and after 40 minutes of exercise.

  • Oxyhemoglobin (micromol)

    Just before, during 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 minutes of exercise, and after 10 minutes of exercise.

  • Deoxyhemoglobin (micromol)

    Just before, during 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 minutes of exercise, and after 10 minutes of exercise.

  • Total hemoglobin (micromol)

    Just before, during 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 minutes of exercise, and after 10 minutes of exercise.

  • Nitric oxide production markers (micromol)

    Before and after 5 minutes of exercise.

Study Arms (2)

Arm crank exercise

EXPERIMENTAL

In the arm-cranking condition, the patients will perform fifteen bouts of two minutes of arm-cranking with an interval of two minutes between bouts, at an intensity equivalent to 13-15 on Borg's subjective perceived exertion scale. The condition will have a total of sixty minutes of duration.

Behavioral: Exercise

Control Condition

SHAM COMPARATOR

The control condition will consist of resting in the standing position for thirty minutes. The patients will be instructed to rest in the sitting position for two minutes at periods equivalent to the intervals from the exercise conditions, totalling sixty minutes of duration.

Behavioral: Exercise

Interventions

ExerciseBEHAVIORAL

Two conditions will be tested: Arm-cranking and control condition.

Arm crank exerciseControl Condition

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • If female, must be postmenopausal without hormone replacement therapy;
  • Non-smokers;
  • With a body mass index (BMI) not exceeding 30 kg/m²;
  • With calf skinfold thickness below 20 mm, due to the interference of adiposity in the penetration of light from the NIRS probe, and oxygen saturation in the finger \>95% to ensure that impaired pulmonary gas exchange does not affect oxygen saturation measurements in the calf;
  • Not using classic antioxidants or vitamin supplements; and
  • Physically capable of performing an exercise session.
  • For the group of participants with PAD, in addition to the criteria mentioned above, they must have a confirmed diagnosis of the disease, characterized by an ankle-brachial index (ABI) lower than 0.90 in one or both legs, exhibit symptoms of claudication during walking, and be physically capable of performing an exercise session to participate in the project.

You may not qualify if:

  • Only participants who discontinue their participation in the study protocol will be excluded from the sample

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Nove de Julho

São Paulo, São Paulo, 01525-000, Brazil

Location

MeSH Terms

Conditions

Peripheral Arterial DiseaseIntermittent ClaudicationMotor Activity

Interventions

Exercise

Condition Hierarchy (Ancestors)

AtherosclerosisArteriosclerosisArterial Occlusive DiseasesVascular DiseasesCardiovascular DiseasesPeripheral Vascular DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsBehavior

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Officials

  • Marilia A Correia, PhD

    University of Nove de Julho

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD

Study Record Dates

First Submitted

February 10, 2025

First Posted

February 14, 2025

Study Start

March 24, 2025

Primary Completion (Estimated)

July 15, 2027

Study Completion (Estimated)

July 15, 2027

Last Updated

April 13, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will share

Individual data may be disclosed upon contact with the principal investigator.

Shared Documents
STUDY PROTOCOL, SAP, CSR

Locations